Trump expected to pick Dr. Heidi Overton to lead FDA

President Donald Trump has reportedly chosen a familiar face to take the reins at the US Food and Drug Administration. Dr. Heidi Overton, a loyalist who has worked closely with the administration, is expected to be nominated as the agency's new commissioner.

This move aims to stabilize the FDA after a period of significant turnover. The position has been open for approximately three months following the departure of the previous chief.

Filling a High-Stakes Vacancy

The leadership change follows the resignation of Dr. Marty Makary. Makary left the post amid reports of mounting friction with the White House regarding the way he managed the agency's operations.

Overton is no stranger to the inner workings of the current administration's health strategy. She is currently serving as the deputy director of the White House’s Domestic Policy Council.

A Background in Policy and Medicine

Dr. Overton is a trained physician with deep roots in conservative health circles. She previously spent time in the first Trump White House before moving into the think tank world.

Before her current role, she led the health policy center at the America First Policy Institute. Her appointment signals a desire for a commissioner who is already aligned with the administration's specific healthcare goals.

Next Steps for the FDA

The White House has not yet released an official statement regarding the nomination. However, sources familiar with the selection process indicate that the announcement is imminent.

If confirmed, Overton will be tasked with leading an agency that has faced intense scrutiny in recent years. Her primary focus will likely involve executing the executive branch's broader medical and regulatory agenda.